



# ImmuBridge™ Multispecific Antibody Discovery & Development Services

## Next-Generation T Cell Engagers, Customized for Your Research Needs

At **Protheragen**, we leverage our advanced ImmuBridge™ platform to provide a full range of multispecific antibody development services—from concept to preclinical validation.

Whether you're developing bispecific, trispecific, or customized TCEs, our platform and expert team support you across the full development cycle.

### Our Services Include:

- **Design & Engineering** of bispecific, trispecific, or multispecific antibodies based on your target antigens and immunomodulatory strategy
- **Expression & Purification** in mammalian systems, with IgG-like format and optimized linker design
- **In Vitro Functional Assays:** Binding affinity, crosslinking-dependent activation, T cell redirection and cytotoxicity
- **In Vivo Evaluation:** Tumor targeting, PK/PD, immunogenicity, and safety assessment
- **Platform-Based Licensing:** Access Protheragen's internal pipelines for licensing

### Ideal for:

- ✓ Biotech & Pharma seeking a flexible multispecific antibody discovery solution
- ✓ Institutions requiring customized antibody engineering or functional screening
- ✓ Teams exploring novel immunotherapy approaches beyond standard BsAbs

# ImmuBridge™: Redefining Multispecific T Cell Engagers (TCEs)

Protheragen's ImmuBridge™ platform enables rapid, modular assembly of multispecific antibodies with optimized tumor-targeting and immune engagement capabilities. These antibodies are engineered with IgG-like architecture, combining tumor-specific antigen recognition with precise T-cell activation domains (e.g., CD3, 4-1BB).

## Platform Advantages

- **IgG-like Structure** – Excellent stability, PK, and manufacturability
- **Cross-linking Dependent Activation** – Tumor-localized immune engagement
- **Flexible Antigen Design** – Supports GPCRs, low-abundance antigens, immune checkpoints
- **Enhanced Immune Synapse Formation** – Potent cytotoxicity, reduced cytokine release
- **High Developability** – Scalable expression, favorable biophysical profiles

## Pipeline

Using the *ImmuBridge™* platform, **Protheragen** has established multiple research pipelines that can be licensed out, helping customers access rich research resources and accelerate the progress of breakthrough antibody therapeutic solutions.

Projects	Antibody	Indication	Discovery	Preclinical	IND	Clinical
MSAD001	HER2/CD3	Breast and gastric cancers	→			
MSAD004	EpCAM/CD3	Colorectal, breast, pancreatic, and ovarian cancers	→			
MSAD007	CD19/CD3	Leukemias and lymphomas	→			
MSAD009	HER2/CD3/CD137	Breast, stomach, and ovarian cancers	→			
MSAD012	EGFR/CD3/CD137	Non-small cell lung cancer and colorectal cancer	→			
MSAD016	CD19/CD3/CD137	B-cell lymphomas, acute lymphoblastic leukemia	→			
MSAD020	CEA/CD3/CD137	Colorectal, gastric and pancreatic cancer	→			
MSAD023	HER2/CD3/CD137/PD-L1	Breast, gastric, esophageal and ovarian cancer	→			
MSAD025	EGFR/CD3/CD137/PD-L1	Non-small cell lung cancer, colorectal cancer	→			
MSAD028	CEA/CD3/CD137/PD-L1	Colorectal, gastric, pancreatic and lung cancer	→			
MSAD029	MUC1/CD3/CD137/PD-L1	Breast, pancreatic, ovarian and lung cancer	→			
MSAD031	EpCAM/CD3/CD137/PD-L1	Colorectal, breast, pancreatic and ovarian cancer	→			
MSAD034	CD19/CD3/CD137/PD-L1	Non-Hodgkin lymphoma, chronic lymphocytic leukemia	→			